Market Tracker

09/20 6:55am ET

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

136.18
Delayed Data
As of Sep 19
 +1.03 / +0.76%
Today’s Change
87.50
Today|||52-Week Range
138.49
+34.02%
Year-to-Date
3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks
Sep 19 / Zacks.com - Paid Partner Content
Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth
Sep 08 / Zacks.com - Paid Partner Content
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
Sep 14 / Zacks.com - Paid Partner Content
Alnylam Shares Plunge on Patient Death, Dosing Suspended
Sep 08 / Zacks.com - Paid Partner Content
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
Sep 12 / Zacks.com - Paid Partner Content
Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?
Sep 07 / Zacks.com - Paid Partner Content
5 Top-Ranked Biotech Stocks to Buy Right Now
Sep 11 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close135.15
Today’s open135.84
Day’s range134.99 - 136.22
Volume383,172
Average volume (3 months)240,511
Market cap$2.8B
Dividend yield--
Data as of 09/19/2017

Growth & Valuation

Earnings growth (last year)-101.05%
Earnings growth (this year)+37.40%
Earnings growth (next 5 years)+27.50%
Revenue growth (last year)+51.53%
P/E ratio358.4
Price/Sales19.42
Price/Book8.28

Competitors

 Today’s
change
Today’s
% change
PBHPrestige Brands Hold...-1.09-2.14%
GWPHGW Pharmaceuticals P...+0.56+0.51%
MDCOMedicines Co-0.76-2.20%
CBPOChina Biologic Produ...-0.24-0.26%
Data as of 09/19/2017

Financials

Next reporting dateNovember 1, 2017
EPS forecast (this quarter)$0.61
Annual revenue (last year)$109.0M
Annual profit (last year)-$2.4M
Net profit margin-2.17%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John L. Higgins
President &
Chief Operating Officer
Matthew W. Foehr
Corporate headquarters
San Diego, California

Forecasts